Document is current
Any future updates will be listed below
-
Authors
Petrosyan, Varduhi https://orcid.org/0000-0002-5356-2002
Dobrolecki, Lacey E. https://orcid.org/0000-0001-6839-629X
LaPlante, Emily L. https://orcid.org/0000-0002-4044-7187
Srinivasan, Ramakrishnan Rajaram https://orcid.org/0000-0001-8087-9200
Bailey, Matthew H.
Welm, Alana L. https://orcid.org/0000-0002-1412-1351
Welm, Bryan E. https://orcid.org/0000-0002-1879-6612
Lewis, Michael T.
Milosavljevic, Aleksandar https://orcid.org/0000-0001-5482-2825
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (5U54 DA036134, U54 CA224076, U54 CA224076)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
A gift from the Korell family for the study of triple negative breast cancer.
- License Information
-
More Information
Article History
Received: 25 October 2021
Accepted: 23 August 2022
First Online: 10 September 2022
Competing interests
: V.P., E.L., R.R., and A.M. have no outside interests to disclose. LD is employed by StemMed Ltd. M.T.L. is a founder of, and equity stake holder in, Tvardi Therapeutics, a founder of, and uncompensated Limited Partner in, StemMed LP, and an uncompensated Manager in StemMed Holdings, its General Partner. He also receives a portion of royalties if Baylor College of Medicine licenses certain PDX models to for-profit entities. The HCI PDX models are licensed by the University of Utah and may result in royalties to A.L.W. an B.E.W.
